ArticleGeroScience2026
Long term cognitive outcome of prodromal and mild dementia with Lewy bodies: a cohort study.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01876459 (Rate of Alpha-synuclein in Cerebrospinal Fluid to Differentiate Patient With Alzheimer's Disease From Those With Lewy Body Disease.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rate of Alpha-synuclein in Cerebrospinal Fluid to Differentiate Patient With Alzheimer's Disease From Those With Lewy Body Disease.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The cognitive evolution of early dementia with Lewy bodies (DLB) is less well known than that of Alzheimer's disease (AD). During dementia, DLB progresses like AD. The aim of this study was to analyze the long-term cognitive decline of early DLB. Participants were recruited for either mild cognitive impairment or mild dementia with a suspicion of DLB or AD, or as healthy older subjects (AlphaLewyMA study, NCT01876459, 2013). Using beta regression, we compared the slope of the Mini-Mental State Examination (MMSE) score of 110 DLB patients (DLB group), 57 AD patients (AD group), 19 DLB and AD patients (DLB + AD group), 30 patients with other cognitive diseases (DC group), and 31 healthy older controls (HC group). The mean follow-up was 4.8 years. All patients' groups had a significant decrease in MMSE score. The slope of MMSE decline of the DLB group (-0.49 point a year) was higher than the HC group (+ 0.03; P < .0001), lower than that of the AD (-2.78; P < .0001) and DLB + AD (-2.92; P < .0001) groups and not different from the DC group (-0.29; P = .8000). The variability of annual variations in MMSE score was greater in the DLB group (2.13 points) than in the AD group (1.73 points). There was no difference between patients' group in terms of death or admission to a nursing home. Patients with early DLB decline cognitively more slowly while fluctuating, whereas AD and DLB + AD patients decline markedly. These results suggest that there is a more dysfunctional than neurodegenerative phase at the beginning of DLB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.